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ABSTRACT
Objectives We evaluated the effectiveness and tolerability 
of linaclotide, a minimally absorbed guanylate cyclase- C 
agonist, in patients with irritable bowel syndrome with 
constipation (IBS- C) in routine clinical practice.
Setting A multicentre, non- interventional study conducted 
between December 2013 and November 2015 across 
31 primary, secondary and tertiary centres in Austria and 
Switzerland.
Participants The study enrolled 138 patients aged ≥18 
years with moderate- to- severe IBS- C. Treatment decision 
was at the physician’s discretion. Patients with known 
hypersensitivity to the study drug or suspected mechanical 
obstruction were excluded. The mean age of participants 
was 50 years, and >75% of the patients were women. 128 
patients completed the study.
Primary and secondary outcome measures Data were 
collected at weeks 0 and 4 in Austria and weeks 0, 4 and 
16 in Switzerland. The primary effectiveness endpoints 
included severity of abdominal pain and bloating (11- point 
numerical rating scale [0=no pain/bloating to 10=worst 
possible pain/bloating]), frequency of bowel movements 
and physicians’ global effectiveness of linaclotide. 
Treatment- related adverse events (AEs) were recorded.
Results Following a 4- week treatment period, the 
mean intensity score of abdominal pain was reduced 
from 5.8 at baseline to 2.7, while the bloating intensity 
score was reduced from 5.8 at baseline to 3.1e (both 
indices p<0.001). The frequency of mean weekly bowel 
movements increased from 2.1 at baseline to 4.5 at 
week 4 (p<0.001). Global effectiveness and tolerability of 
linaclotide were assessed by the treating physicians as 
‘good’ or ‘excellent’ in >70% of patients. In total, 31 AEs 
were reported in 22 patients, the most common being 
diarrhoea, reported by 6 (7%) and 8 (15.4%) patients in 
Austria and Switzerland, respectively.
Conclusions Patients with IBS- C receiving linaclotide 
experienced effective treatment of moderate- to- severe 
symptoms in routine clinical practice. Linaclotide was 
safe and well tolerated and no new safety concerns were 
raised, supporting results from previous clinical trials.
InTROduCTIOn
Irritable bowel syndrome (IBS) is a func-
tional gastrointestinal (GI) disorder char-
acterised by recurrent abdominal pain or 
discomfort and change in bowel habits.1 IBS 
is a common GI ailment, with global preva-
lence ranging from 3% to 21%, depending 
on the diagnostic criteria.2 The prevalence 
of IBS in Europe is estimated at 12%–15%.3 
IBS is subtyped based on the predominant 
stool pattern, and includes IBS subtype with 
constipation (IBS- C), diarrhoea (IBS- D), 
mixed stool (IBS- M) or un- subtyped (IBS- U) 
when stool consistency does not meet criteria 
for IBS- C, IBS- D or IBS- M.4 When defined by 
Rome III diagnostic criteria, IBS is prevalent 
in approximately 1%–29% of the general 
population, with IBS- C present in 1%–4%.5 
Of the IBS subtypes, IBS- C is the second most 
Strengths and limitations of this study
 ► This is the first real- world study evaluating the ef-
fectiveness and tolerability of an irritable bowel 
syndrome with constipation treatment in the Alpine 
region.
 ► This study sought to evaluate whether the efficacy 
and tolerability of linaclotide that was demonstrated 
in randomised clinical trials could be recapitulated in 
clinical practice in a real- world setting.
 ► Results from the physicians’ global assessment of 
efficacy and tolerability will be useful in determining 
physician comfort level with prescribing linaclotide 
for their patients.
 ► This was a non- interventional study that lacked a 
placebo control; thus, the statistical analyses are 
descriptive and exploratory in nature.
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common subtype, comprising approximately 35% of all 
IBS cases.3
In addition to abdominal pain and discomfort, patients 
with IBS- C often experience hard or lumpy stools, 
straining, feeling of incomplete evacuation and bloating. 
Moreover, IBS- C has an undue impact on quality of life, 
increases healthcare costs and reduces work produc-
tivity.6 7 Since IBS- C presents with a constellation of symp-
toms, therapy options have centred on symptom relief 
and have generally included dietary and lifestyle modi-
fications, and over- the- counter medications such as fibre 
supplements and laxatives which aim to relieve consti-
pation. However, these treatments are often ineffective 
and patients resort to additional therapies, which in turn 
drives up healthcare costs and resources, thus under-
scoring the need to identify efficacious treatment options 
for IBS- C.8
Linaclotide is a minimally absorbed 14- amino acid 
guanylate cyclase- C (GC- C) receptor agonist structurally 
related to the guanylin peptide family.9 On binding to 
GC- C receptors, linaclotide increases the intracellular 
production of cyclic guanosine monophosphate (cGMP), 
which in turn activates the cystic fibrosis transmembrane 
conductance regulator, resulting in secretion of chloride 
and bicarbonate into the intestinal lumen, ultimately 
accelerating intestinal transit.10 Linaclotide was demon-
strated to increase colonic transit and reduce abdominal 
pain and constipation in patients with IBS- C in phase II 
trials.11 12 Subsequently, the efficacy and safety of lina-
clotide for the treatment of IBS- C was established in two 
placebo- controlled phase III trials that showed improve-
ments in IBS- C symptoms, including abdominal pain and 
bowel movements.9 13
Linaclotide was approved by the Food and Drug 
Administration (FDA) and European Medicines Agency 
in 2012 for the symptomatic treatment of adults with 
moderate- to- severe IBS- C.14 15 While the efficacy and 
safety of linaclotide have been established in clinical trial 
settings, these may not depict real- life experiences. To 
address this need, observational studies were undertaken 
to evaluate the effectiveness and safety of linaclotide in 
real- world settings in Europe. In routine clinical practice, 
linaclotide has recently been shown to be effective in 
improving IBS- C symptoms in a post- marketing authori-
sation study conducted in Germany.16 Herein, we aimed 
to document the effectiveness and safety of linaclotide 
for the treatment of moderate- to- severe IBS- C in adults 
under real- life conditions in the Alpine region of Austria 
and Switzerland.
MeThOdS
Study design
This was a multicentre, open, observational, non- 
interventional study (NIS) evaluating the effectiveness 
and safety of linaclotide for the treatment of moderate- to- 
severe IBS- C in adult patients under real- life routine clin-
ical practice conditions in Austria and Switzerland. There 
were no treatment groups or actions to which patients 
were randomly assigned. A total of 200 patients were 
planned for enrolment across 40 sites in each country. 
The study was conducted from December 2013 to March 
2015 in Austria and from November 2014 to November 
2015 in Switzerland.
The study comprised a 4- week treatment period 
commencing with visit 1 at treatment initiation and 
visit 2 occurring approximately 4 weeks after initiation 
in Austria. In Switzerland, data were collected over the 
course of three visits, at 0, 4 and 16 weeks after treatment 
initiation. Linaclotide was administered per the usual 
therapeutic procedure of the attending physician and in 
accordance with the indication for the drug (290 µg once 
daily, taken at least 30 min before meals).15
All participants provided written, informed consent 
prior to study initiation.
Participants
Eligible patients were aged ≥18 years with a diagnosis 
of moderate- to- severe IBS- C (diagnosed by the treating 
physician), characterised by clinical evidence of relevant 
interference of symptoms with well- being and/or daily 
routines at work or during leisure. The decision to treat 
a patient with linaclotide was made solely by the treating 
physician prior to inclusion in the study. Patients with 
known hypersensitivity to the active ingredient or any 
other component of linaclotide, with suspected or known 
GI obstruction or who were pregnant or planning to 
become pregnant were excluded from the study.
Study assessments
All relevant data collected during routine treatment with 
linaclotide were recorded in case report forms. Patient 
demographics and medical history were collected, 
including diagnosis, prior treatment and symptoms of 
IBS- C, comorbidities and concomitant medications.
The primary effectiveness endpoints included severity 
of abdominal pain and bloating, frequency of bowel 
movements during the week before each visit, general 
symptom improvement relative to pretreatment, physi-
cians’ satisfaction with linaclotide therapy, sensation of 
incomplete bowel evacuation, change in predominant 
stool consistency and physicians’ global assessment of 
the effectiveness of linaclotide. Changes in the severity 
of abdominal pain and bloating were measured using 
an 11- point numerical rating scale (NRS; 0=no pain/
bloating to 10=worst possible pain/bloating). Physicians’ 
satisfaction with linaclotide therapy was measured using 
an 11- point NRS (0=very satisfied to 10=totally unsatis-
fied). General symptom improvement and improvement 
in three individual symptoms—abdominal pain, bloating 
and constipation—were measured by patient response 
to simple yes/no questions asked by the physician (eg, 
‘Have symptoms improved over the last week compared 
with the time prior to therapy start?’). Frequency of bowel 
movements during the week before each visit, sensation 
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of incomplete bowel evacuation and change in predomi-
nant stool consistency were patient- reported.
Adverse events (AEs) related to linaclotide treatment 
or whose relation to linaclotide treatment could not be 
excluded were documented. AEs assessed by the physi-
cian as not related to linaclotide treatment were not 
documented. Other safety measures included physicians’ 
global assessment of the tolerability of linaclotide.
Statistical analyses
Statistical analysis was performed using SAS V.9.4 soft-
ware (SAS Institute). Data were analysed using descriptive 
statistics and no hypotheses were pre- specified. To deter-
mine whether the pre–post changes of symptoms were 
statistically significant, the Wilcoxon signed- rank test was 
applied. Reported p values are two- tailed, using an alpha 
level of 0.05 to assess statistical significance. Missing data 
were imputed using the last observation carried forward 
method. Visit 1 and 2 efficacy data were compiled for 
both countries, where applicable.
Patient and public involvement
This was an observational study. Patients continued on 
existing medication at their own discretion. Study outcomes 
were scored by the patients and the data collected during 
this study were informed by the patients’ experiences.
ReSulTS
Patient characteristics
A total of 86 patients in 22 sites and 52 patients in nine 
sites were enrolled in Austria and Switzerland, respec-
tively. Baseline characteristics were generally comparable 
between the two countries. Of the enrolled patients, 71 
(82.6%) in Austria and 40 (76.9%) in Switzerland were 
women, and the mean age was 51 and 49 years, respec-
tively (table 1). The mean body mass index was 24 and 
23 kg/m2 in each country. The average time since IBS- C 
diagnosis was 2.1 and 5.2 years for patients in Austria and 
Switzerland, respectively. At baseline, >90% of patients in 
both countries reported abdominal pain (mean intensity 
scores of 6.0 and 5.4, respectively) and bloating (mean 
intensity scores of 5.8 and 5.6, respectively). Patients in 
both countries reported a mean of 2.1 bowel movements 
per week. Prior treatment for IBS- C was reported by 73 
(84.9%) patients in Austria and 49 (94.2%) patients in 
Switzerland, mainly consisting of laxatives and dietary 
fibres, while 33 (38.4%) patients in Austria and 16 
(30.8%) patients in Switzerland received concurrent IBS 
treatment. Concomitant diseases were reported by 35 
(40.7%) patients in Austria and 10 (19.2%) patients in 
Switzerland (table 1). Collectively, baseline characteris-
tics of the patients with IBS- C in this study were reflective 
of the general IBS patient population (ie, approximately 
70% of IBS patients are typically women, with a high like-
lihood of the majority of patients being ≤50 years).
Throughout the course of the study, 20 (23.3%) 
patients in Austria and 17 (32.7%) patients in Switzerland 
discontinued linaclotide treatment, with the main 
reasons for discontinuation being lack of effectiveness for 
13 (15.1%) patients in Austria and AEs for 10 (19.2%) 
patients in Switzerland. Reasons for treatment discontin-
uation are summarised in table 2.
effectiveness outcomes
Effect of linaclotide treatment on symptoms of IBS-C
Linaclotide was administered over 4 weeks in Austria and 
16 weeks in Switzerland, and data from the initial 4- week 
treatment periods are compiled in this analysis. Of the 
138 enrolled patients, data were available for 128 patients 
at week 4. Improvements in abdominal pain, bloating 
and bowel movements were observed after 4 weeks of 
treatment with linaclotide. From a mean intensity score 
of 5.8 at baseline, abdominal pain was reduced to 2.7 
after 4 weeks of treatment in both countries (figure 1A; 
p<0.001 vs visit 1; 11- point NRS [0=no pain to 10=worst 
possible pain]). In Switzerland, continued reduction in 
abdominal pain was observed at week 16, with a mean 
intensity score of 2.5 (SD ±2.0; n=51; p<0.0001 vs visit 1). 
Improvements in bloating were also seen after 4 weeks of 
treatment in both countries; from a baseline mean inten-
sity score of 5.8, the bloating score was reduced to 3.1 at 
week 4 (figure 1B; p<0.001 vs visit 1; 11- point NRS [0=no 
bloating to 10=worst possible bloating]), with a mean 
intensity score of 3.0 (SD ±2.2; n=51; p<0.0001 vs visit 1) 
at week 16 in Switzerland. Furthermore, the frequency of 
bowel movements increased from a mean of 2.1 per week 
at baseline to 4.5 at week 4 (figure 1C; p<0.001 vs visit 1) 
in both countries, and to 4.7 (SD ±1.6; n=51; p<0.0001 vs 
visit 1) at week 16 in Switzerland.
Data were stratified based on patients who received 
prior IBS- C treatment, and improvements in IBS- C symp-
toms were observed within the 4- week treatment period, 
regardless of prior IBS- C treatment. Significant reductions 
from week 1 to week 4 in mean abdominal pain intensity 
and mean bloating intensity were seen in patients who 
had received laxative pretreatment and in those who 
had not received prior IBS- C treatment (figure 2A,B; all 
p<0.001 vs visit 1). Similar degrees of mean reduction in 
abdominal pain were seen in patients who did not and 
in those who did receive laxative pretreatment (both 
3.1). Furthermore, the effect of concomitant laxative use 
with linaclotide was evaluated. Our results showed that 
significant reduction was achieved after 4 weeks of treat-
ment in mean abdominal pain intensity (figure 3A; all 
p<0.001 vs visit 1) and mean bloating intensity (figure 3B; 
all p<0.001 vs visit 1), both in patients who used laxatives 
concomitantly with linaclotide and in those who did not. 
Greater symptom improvement was observed in those 
who did not use concomitant treatment (mean reduction 
in abdominal pain: 3.5 vs 1.9; mean reduction in bloating: 
3.0 vs 1.9; figure 3A,B; all differences p<0.001 vs visit 1).
Patient assessment of improvement in IBS-C symptoms
At each respective end- of- treatment period, patients were 
asked to indicate their sense of general improvement in 
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Table 1 Patient baseline demographics and characteristics
Austria (n=86) Switzerland (n=52)
Female, n (%) 71 (82.6) 40 (76.9)
Mean age, years 51.3 49.2
Mean BMI, kg/m² 24.0 23.4
Average time since diagnosis, years 2.1 5.2
Received pretreatment, n (%) 73 (84.9) 49 (94.2)
  Laxatives 67 (77.9) 41 (78.9)
  Dietary fibres 55 (64.0) 36 (69.2)
Concomitant disease, n (%) 35 (40.7) 10 (19.2)
  Hypertension 9 (10.5) 5 (9.6)
Received concurrent IBS treatment, n (%) 33 (38.4) 16 (30.8)
  Laxatives 22 (25.6) 13 (25.0)
  Osmotic 18 (20.9) 6 (11.5)
  Macrogol, combinations 9 (10.5) 5 (9.6)
  Lactulose 5 (5.8) 1 (1.9)
  Magnesium citrate 3 (3.5) 0
  Sodium phosphate 1 (1.2) 0
  Magnesium hydroxide 0 2 (3.9)
  Bulk- forming 0 5 (9.6)
  Sterculia 0 4 (7.7)
  Ispaghula (psylla seeds) 0 1 (1.9)
  Stimulant 17 (19.8) 7 (13.5)
  Bisacodyl 8 (9.3) 3 (5.8)
  Sodium picosulfate 5 (5.8) 2 (3.9)
  Senna glycosides, combinations 2 (2.3) 2 (3.9)
  Carbon dioxide- producing drugs 2 (2.3) 0
  Stimulant/stool softener 0 2 (3.9)
  Glycerol 0 2 (3.9)
  Stool softener 0 2 (3.9)
  Liquid paraffin, combinations 0 2 (3.9)
  Patients experiencing abdominal pain at baseline, n (%) 85 (98.8) 46 (90.2)
  Mean intensity score of abdominal pain at baseline (SD) 6.0 (±2.1) 5.4 (±2.7)
  Patients experiencing bloating at baseline, n (%) 81 (95.3) 48 (94.1)
  Mean intensity score of bloating at baseline (SD) 5.8 (±2.4) 5.6 (±2.7)
  Mean number of bowel movements/week (SD) 2.1 (±1.3) 2.1 (±1.4)
  Solid stool consistency, n (%) 55 (64.0) 22 (44.0)
  ‘Morning’ was most commonly advised time of intake, n (%) 68 (80.0) 26 (53.1)
% are calculated from total number of patients providing data for that outcome. Laxatives reported by type and chemical substance.
Baseline IBS symptoms were assessed during the week before start of therapy; 0=no pain/bloating; 10=worst pain/bloating.
BMI, body mass index; IBS, irritable bowel syndrome.
symptoms as compared with the pretreatment period. In 
Austria, 74 (87.1%) patients reported overall improved 
symptoms, among whom 56 (65.9%) patients experi-
enced improvements in abdominal pain, 60 (70.6%) 
had improvements in bloating and 65 (76.5%) reported 
improvements in constipation at visit 2 compared with 
baseline (figure 4). In Switzerland, 45 (88.2%) patients 
reported overall improved symptoms, consisting of 
38 (74.5%) patients with improvements in abdominal 
pain, 35 (68.6%) with improvements in bloating and 42 
(82.4%) reporting improvements in constipation after 16 
weeks of treatment compared with baseline (figure 4).
Physician assessment of satisfaction and effectiveness of 
linaclotide therapy
Physicians’ satisfaction with linaclotide treatment was 
assessed on a scale from 0 (very satisfied) to 10 (totally 
unsatisfied). In Austria, mean satisfaction was 2.9 (SD 
Zentralbibliothek Zuerich. Protected by copyright.
 o
n
 February 3, 2020 at UZH Hauptbibliothek /
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025627 on 30 December 2019. Downloaded from 
5Pohl D, et al. BMJ Open 2019;9:e025627. doi:10.1136/bmjopen-2018-025627
Open access
Table 2 Reasons for discontinuing linaclotide
Austria 
(n=86)
Switzerland 
(n=52)
Discontinued patients, n (%) 20 (23.3) 17 (32.7)
  Lack of effectiveness 13 (15.1) 5 (9.6)
  Adverse events 8 (9.3) 10 (19.2)
  Improvement in symptoms 5 (5.8) 5 (9.6)
  Lack of compliance 1 (1.2) 0
  Excessive drug effect 0 1 (1.9)
Austria: Seven patients reported two reasons each.
Switzerland: Four patients reported two reasons each.
Figure 1 Effect of linaclotide treatment on (A) abdominal 
pain, (B) bloating and (C) frequency of bowel movements 
in all patients. Visits 1 and 2 refer to baseline and week 4, 
respectively.
Figure 2 Effect of linaclotide treatment in patients with and 
without prior treatment for irritable bowel syndrome with 
constipation on (A) abdominal pain and (B) bloating. Visits 1 
and 2 refer to baseline and week 4, respectively.
Figure 3 Effect of linaclotide treatment in patients with and 
without concomitant treatment for irritable bowel syndrome 
with constipation on (A) abdominal pain and (B) bloating. 
Visits 1 and 2 refer to baseline and week 4, respectively.
±3.0; median 2.0) points after 4 weeks of treatment, indic-
ative of ‘good satisfaction’, with at least 60% of the 83 
total patients rated a score of ≤2.0 by their treating physi-
cians. In Switzerland, mean satisfaction was 4.6 (SD ±3.2; 
median 3.0) points after 16 weeks of treatment, indicative 
of ‘moderate satisfaction’, with at least 50% of the 51 total 
patients rated a score of ≤3.0 by their treating physicians 
(figure 5A). Furthermore, physicians assessed the global 
effectiveness of linaclotide treatment at the end of the 
treatment periods, and at visit 2 linaclotide effectiveness 
was evaluated as ‘excellent’ in 33 (38.4%) patients, ‘good’ 
in 30 (34.9%) patients, ‘moderate’ in 14 (16.3%) patients 
and ‘poor’ in 9 (10.5%) patients in Austria. In Switzer-
land, physicians assessed linaclotide effectiveness as 
‘excellent’ in 18 (37.5%) patients, ‘good’ in 21 (43.8%) 
patients and ‘moderate’ in 9 (18.8%) patients, with the 
effectiveness not rated as ‘poor’ in any patient after 16 
weeks of treatment (figure 5B).
Physicians were also asked to indicate the rationale for 
initiating linaclotide treatment. In Austria, linaclotide was 
prescribed due to low efficacy of previous medication for 
39 (45.4%) patients; for 3 (3.5%) patients, linaclotide was 
prescribed due to low tolerability of previous medication; 
and for 52 (60.5%) patients, linaclotide was a new prescrip-
tion, whose treatment rationale was not a consequence 
of any previous medication. In Switzerland, 31 (59.6%) 
patients were prescribed linaclotide due to low efficacy of 
previous medication, 3 (5.8%) patients were prescribed 
linaclotide due to low tolerability of previous medication, 
while 20 (38.5%) patients received linaclotide as a new 
IBS- C prescription and not due to any previous medication.
Use of concomitant medications
Concomitant medication use was reported in 31 (36.1%) 
and 13 (25.0%) patients in Austria and Switzerland, 
respectively, with the most common being antihyper-
tensive renin–angiotensin system agents in both coun-
tries, used by 7 (8.1%) patients in Austria and 6 (11.5%) 
patients in Switzerland. A summary of concomitant medi-
cation use by Anatomical Therapeutic Chemical classifi-
cation system is presented in table 3.
Safety and tolerability
Summary of AEs
Sixteen AEs were reported in 10 (11.6%) patients in 
Austria after 4 weeks of treatment and 15 AEs were 
reported in 12 (23.1%) patients in Switzerland after 16 
weeks of treatment (table 4). The most common AE was 
diarrhoea, which occurred in 6 (7.0%) and 8 (15.4%) 
patients in Austria and Switzerland, respectively. Drug 
ineffectiveness was reported as an AE for 5 (5.8%) 
patients in Austria and 2 (3.9%) patients in Switzerland. 
AEs leading to treatment discontinuation occurred in 
8 (9.3%) patients in Austria and 10 (19.2%) patients 
in Switzerland (table 2). AEs leading to dose reduction 
occurred in 2 (2.3%) patients in Austria. The majority of 
AEs were mild or moderate in intensity, while severe AEs 
were reported in 2 (2.3%) patients (2 events; 1 abdom-
inal distension and 1 rectal tenesmus) in Austria and 4 
(7.7%) patients (5 events; 4 diarrhoea and 1 urge inconti-
nence) in Switzerland. An AE was considered severe if the 
intensity of the symptoms significantly interfered with a 
patient’s daily activities. Of all 31 reported AEs, treatment 
causality was confirmed for 11 AEs reported by 8 (9.3%) 
patients in Austria and 14 (23.1%) AEs reported by 12 
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Figure 4 Proportion of patients reporting overall and 
individual improvement in irritable bowel syndrome with 
constipation symptoms at the end- of- treatment periods 
(week 4 in Austria and week 16 in Switzerland). Proportions 
are based on the number of patients with available data at 
respective end- of- treatment visits (Austria, n=85; Switzerland, 
n=51).
Figure 5 Physicians’ assessment of (A) satisfaction, and 
global assessment of (B) effectiveness and (C) tolerability 
of linaclotide. Satisfaction data in (A) presented on a scale 
of 0 (very satisfied) to 10 (totally unsatisfied); Austria, mean 
2.9±3.0 points (‘good’ satisfaction); Switzerland, mean 
4.6±3.2 points (‘moderate’ satisfaction).
patients in Switzerland. No serious AEs (ie, AEs that were 
life- threatening) were reported in either country over the 
respective 4- week or 16- week treatment periods.
Physician assessment of linaclotide tolerability
Treating physicians assessed the global tolerability of 
linaclotide treatment, and after 4 weeks of treatment 
linaclotide tolerability was evaluated as ‘excellent’ in 
44 (51.2%) patients, ‘good’ in 28 (32.6%) patients, 
‘moderate’ in 11 (12.8%) patients and ‘poor’ in 3 (3.5%) 
patients in Austria. In Switzerland, physicians assessed 
linaclotide tolerability as ‘excellent’ in 24 (49.0%) 
patients, ‘good’ in 13 (26.5%) patients, ‘moderate’ in 7 
(14.3%) patients and ‘poor’ in 5 (10.2%) patients after 
16 weeks of treatment (figure 5C).
dISCuSSIOn
In this NIS, the effectiveness, safety and tolerability of lina-
clotide were evaluated in patients with moderate- to- severe 
IBS- C under real- life settings in Austria and Switzerland. 
We observed improvements in abdominal pain, bloating 
and frequency of bowel movements following a 4- week 
treatment period in both countries, which were further 
sustained over 12 additional weeks in Switzerland. Signifi-
cant improvements in abdominal pain and bloating were 
observed both in patients who received prior laxative treat-
ment and in those who did not receive IBS- C pretreatment. 
However, between patients who administered laxatives 
concomitantly with linaclotide treatment and those who 
did not, the degree of reduction after 4 weeks of treatment 
in mean intensity score in IBS- C symptoms suggests that 
concomitant laxative use diminished linaclotide effect. 
Importantly, treating physicians rated both the effectiveness 
and tolerability of linaclotide as ‘good’ or ‘excellent’ for a 
majority of patients. Few AEs were reported in this study, 
none of which were serious AEs, and no new safety signals 
were observed throughout the study.
Abdominal pain is the major clinical manifestation of 
IBS and is challenging to treat. Moreover, abdominal pain 
is highly correlated with IBS disease severity and higher 
economic burden.17–19 In the present study, >90% of all 
patients reported abdominal pain at baseline, with mean 
intensity scores of 6.0 in Austria and 5.4 in Switzerland, 
measured using the 11- point NRS. Clinically relevant 
change in the 11- point NRS for pain intensity was previ-
ously evaluated using data from 10 placebo- controlled 
trials that included 2724 patients with chronic pain (post- 
herpetic neuralgia, osteoarthritis, diabetic neuropathy, 
chronic low back pain and fibromyalgia).20 By relating the 
11- point NRS to the 7- point Patient Global Impression of 
Change with categories of ‘much improved’ and ‘very 
much improved’ used to determine a clinically relevant 
difference, a reduction of 2 points or 30% in the 11- point 
NRS was deemed clinically relevant.20 A 10- point NRS for 
pain intensity was evaluated in a cohort of 277 patients 
with IBS from the PROOF cohort, where the minimal 
clinically important difference was determined as 2.2 
points or a 29.5% reduction in the NRS.19 Our findings 
showed that, collectively, the mean intensity of abdominal 
pain decreased from a baseline NRS level of 5.8 to 2.7 
after 4 weeks of linaclotide treatment, corresponding to 
a 53% reduction in abdominal pain in both countries. In 
Austria, the reduction in mean abdominal pain intensity 
score was 3.5 points (57%) at 4 weeks, while reductions 
of 2.2 points (41%) at 4 weeks and 2.9 points (53%) after 
16 weeks were observed in Switzerland. These reductions 
are consistent with those previously validated as clinically 
relevant change in pain intensity.19 20
In a recent NIS conducted in Germany, linaclotide 
treatment resulted in a reduction in mean pain inten-
sity score of 1.72 points (35%) at 4 weeks and 2.5 points 
(50%) at 12 months after treatment initiation.16 Data 
from these European real- world studies demonstrate 
that improvements in abdominal pain are observed in 
linaclotide- treated patients within the first month of 
treatment initiation and are sustained throughout the 
respective treatment periods. Mechanistically, as a GC- C 
receptor agonist, linaclotide is believed to increase extra-
cellular cGMP levels, which in turn reduces the firing of 
pain- sensing visceral afferent fibres, resulting in an anal-
gesic effect, thus reducing abdominal pain.21
Zentralbibliothek Zuerich. Protected by copyright.
 o
n
 February 3, 2020 at UZH Hauptbibliothek /
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025627 on 30 December 2019. Downloaded from 
7Pohl D, et al. BMJ Open 2019;9:e025627. doi:10.1136/bmjopen-2018-025627
Open access
Table 3 Use of concomitant medications
Austria (n=86) Switzerland (n=52)
Patients receiving at least one concomitant medication, n (%) 31 (36.1) 13 (25.0)
  Renin–angiotensin system agents 7 (8.1) 6 (11.5)
  Psychoanaleptics 6 (7.0) 2 (3.9)
  Beta- blocking agents 4 (4.7) 4 (7.7)
  Lipid- modifying agents 4 (4.7) 4 (7.7)
  Psycholeptics 3 (3.5) 0
  Diabetes drugs 3 (3.5) 0
  Analgesics 0 3 (5.8)
  Drugs for acid- related disorders 0 2 (3.9)
Concomitant medications reported by anatomical main group.
Table 4 Summary of safety
Austria 
(n=86)
Switzerland 
(n=52)
Total AEs 16 15
Serious AEs 0 0
Patients with ≥1 AEs, n (%) 10 (11.6) 12 (23.1)
  Diarrhoea 6 (7.0) 8 (15.4)
  Drug ineffective 5 (5.8) 2 (3.9)
  Abdominal distension 2 (2.3)* 0
  Dizziness 0 1 (2.0)
  Condition aggravated 1 (1.2) 0
  Rectal tenesmus 1 (1.2) 0
  Headache 0 1 (1.9)
  Hot flush 0 1 (1.9)
  Nausea 0 1 (1.9)
  Urge incontinence 0 1 (1.9)
AEs recorded per preferred term using Medical Dictionary for 
Regulatory Activities V.18.0 (Austria) and V.18.1 (Switzerland).
*Two abdominal distension events reported for one patient.
AEs, adverse events.
In addition to improvements in abdominal pain, 
significant improvements in bloating were also observed 
following 4 weeks of treatment with linaclotide. At base-
line, >94% of all patients reported bloating, and an 
overall reduction of 2.8 points (47%) was observed after 
the 4- week treatment period in both countries, which 
was sustained after 16 weeks of treatment in Switzer-
land. Moreover, in both countries, linaclotide treatment 
increased the mean frequency of bowel movements from 
a mean of 2.1 times a week at baseline to 4.5 times a 
week. These observations are in line with previous animal 
studies which showed that linaclotide increases GI transit 
and fluid secretion via accumulation of intracellular 
cGMP in a dose- dependent manner.22
At study initiation, >84% of patients in this study had 
received IBS- C pretreatment, mainly comprising laxatives 
or dietary fibres. We found that linaclotide was effective 
in managing symptoms of patients, regardless of prior 
treatment or concomitant medication use. In fact, our 
data found that a greater degree of improvement was 
observed in patients who did not use concomitant IBS- C 
treatment as compared with those who used concomitant 
laxatives (mean reduction in abdominal pain: 3.5 vs 1.9; 
mean reduction in bloating: 3.0 vs 1.9), suggesting that 
laxatives might interfere with the efficacy of linaclotide. 
Laxatives such as polyethylene glycol are often used as 
first- line therapy for patients with IBS- C; however, their 
effect on improvements in abdominal pain or bloating is 
inconsistent.1 23 A recent consensus report recommended 
against the co- administration of linaclotide with laxatives, 
especially at the beginning of treatment due to poten-
tial diarrhoeal side effects, and only suggested co- ad-
ministration in cases of partial response to linaclotide.2 
How concomitant laxatives may impact the efficacy of 
linaclotide is currently unclear. Osmotic laxatives may 
improve the frequency and consistency of bowel move-
ments but have no impact on abdominal pain or bloating; 
moreover, some stimulant laxatives (for which there are 
no randomised controlled trials [RCTs] in IBS- C) may 
relieve chronic constipation but result in abdominal pain 
and cramping.1 In real- life settings, some patients may 
choose to add laxative treatment based on the severity 
of constipation, or water- binding agents may be titrated 
with linaclotide to gradually improve stool consistency; 
however, both of these strategies may inadvertently lessen 
the efficacy of linaclotide by binding excess fluids. None-
theless, the present data demonstrate that linaclotide can 
effectively manage IBS- C symptoms irrespective of treat-
ment history, and it does not require co- administration 
with other IBS- C medications, specifically laxatives.
The results of this study support the findings from 
pivotal phase III RCTs that evaluated the efficacy and 
safety of linaclotide in IBS- C.9 13 24 25 Two of the RCTs used 
the FDA’s responder criteria of improvement of ≥30% 
from baseline in average daily worst abdominal pain score 
and an increase of ≥1 in complete spontaneous bowel 
movements (CSBMs) per week. In the first double- blind, 
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placebo- controlled, 26- week study of 804 participants, 
49% of patients treated with linaclotide exhibited ≥30% 
improvement in abdominal pain (corresponding to a 2.1- 
point decrease) and 48% experienced an increase of ≥1 
in weekly CSBMs (corresponding to a 2.2- point decrease) 
for at least 6 of the 12 treatment weeks.9 Moreover, lina-
clotide treatment resulted in increases in spontaneous 
bowel movements (SBMs) per week by 3.8 and CSBMs 
per week by 2.2. In the second pivotal multicentre, 
double- blind, placebo- controlled study with 800 patients 
with IBS- C treated over 12 weeks, linaclotide resulted in 
significant improvements in abdominal pain (1.9- point 
worst abdominal pain improvement), bloating (1.9- point 
improvement), SBMs per week (+3.9 frequency) and 
CSBMs per week (+2.3 frequency).13
Global tolerability of linaclotide treatment was assessed 
as ‘good’ or ‘excellent’ in >75% of patients by their 
treating physicians in both countries in the current study. 
Moreover, physicians’ satisfaction with linaclotide therapy 
was evaluated on a 0–10 scale (‘very satisfied’ to ‘totally 
unsatisfied’), with scores of 2.9 (‘good’ satisfaction) after 
4 weeks in Austria and 4.6 (‘moderate’ satisfaction) after 
16 weeks in Switzerland. In comparison, 45% and 52% 
of patients treated with linaclotide noted satisfaction with 
linaclotide in the two RCTs, while 62% of treating physi-
cians rated the effectiveness of linaclotide as ‘good’ or 
‘excellent’ in Germany in a recent NIS.9 13 16 Previously, 
an 18- month long- term safety study demonstrated similar 
patient satisfaction between linaclotide- treated patients 
who experienced diarrhoea as compared with those who 
did not, and >85% reported moderate satisfaction during 
the treatment period, indicating a high degree of treat-
ment satisfaction irrespective of AEs.26
Diarrhoea has previously been reported as a potential 
consequence of linaclotide- mediated increase in GI transit 
and fluid secretion and, as such, was the most commonly 
reported AE during this study (7% of patients in Austria 
and 15% of patients in Switzerland). All events were mild or 
moderate in severity. In the phase III RCTs, diarrhoea was 
reported by 19.5% of patients in the study by Chey et al,9 and 
by 19.7% in the study by Rao et al.13 The discrepancy in diar-
rhoea rates between this NIS and the previous RCTs may 
be due to the difference in reporting methods. Addition-
ally, the lower incidence of adverse drug reactions reported 
in this NIS may be due to under- reporting by physicians of 
AEs already described in the summary of product charac-
teristics.27 Finally, the impact of concomitant laxative use on 
diarrhoea cannot be discounted.
Treatment options for IBS- C are limited, with traditional 
therapies showing limited effectiveness in improving 
symptoms and quality of life, and only four pharmacolog-
ical agents are approved for use. One such FDA- approved 
agent is lubiprostone, a chloride channel activator that was 
shown to improve IBS- C symptoms in two RCTs; however, 
lubiprostone is not approved for treatment in men due to 
limited efficacy.28 Recently, plecanatide, a GC- C receptor 
agonist in the same drug class as linaclotide, was approved 
for the treatment of IBS- C based on data from two RCTs, 
with a safety and efficacy profile comparable with that of 
linaclotide RCTs; however, no evidence from real- life clin-
ical settings currently exists for plecanatide.29 30 Another 
FDA- approved agent for IBS- C is tegaserod, a prokinetic 
agent that was approved in 2002 but was withdrawn from 
the market in 2007 due to increased cardiovascular risks.31 
The FDA recently approved its reintroduction for use in 
adult women <65 years of age with IBS- C.32
Some limitations are associated with this study, which 
necessitate caution when interpreting the findings. The 
main limitations are the sample size and differing study 
durations between the two countries, which allowed 
compilation of only 4 weeks of data. Another limitation is 
that satisfaction with linaclotide was a physician- measured 
outcome, as compared with a patient- measured outcome 
in the clinical trials, which may lead to potential bias. The 
FDA’s composite primary endpoint for IBS- C (responder: 
improvement of ≥30% in average daily worst abdominal 
pain score and increase of ≥1 CSBMs from baseline, both 
in the same week for at least 50% of weeks assessed) was 
used in the two clinical trials of linaclotide to determine 
efficacy.9 13 In the present study, the lack of a composite 
primary endpoint may have led to inflation in the effi-
cacy of linaclotide when compared with the clinical trials. 
As the diagnosis of moderate- to- severe IBS- C was deter-
mined by the treating physician without strict diagnosis 
criteria, selection bias may have occurred. In addition, as 
this was an NIS without a placebo control, the statistical 
analyses are descriptive and explorative, and no statis-
tical hypotheses were pre- specified. Nevertheless, to the 
best of our knowledge, no real- world studies have been 
conducted evaluating IBS- C treatments in the Alpine 
region, and observational studies were thus undertaken 
to evaluate the effectiveness and safety of linaclotide in 
real- world settings in various European countries, with 
data recently published from Sweden,33 the UK34 and 
Germany.16 Our current findings suggest that linaclotide 
is safe and effective in reducing major symptoms of IBS- C 
in routine clinical practice in Austria and Switzerland. 
These data support the previously reported results from 
two randomised phase III clinical trials that collectively 
demonstrate the efficacy and safety of linaclotide treat-
ment for the management of patients with IBS- C with 
moderate- to- severe abdominal symptoms.
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